GnRH agonists and uterine leiomyomas

Human Reproduction

Volumn 11, Issue SUPPL. 3, 1996, Pages 3-25

  Broekmans, F J ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

GnRH agonists; Leiomyoma treatment; Pre treatment; Surgery

Indexed keywords

ESTROGEN; GONADORELIN AGONIST; PROGESTERONE;

AMENORRHEA; CONFERENCE PAPER; DEPRESSION; DRUG MECHANISM; DYSPAREUNIA; FEMALE; FEMALE SEXUAL DYSFUNCTION; HEADACHE; HOT FLUSH; HUMAN; HYSTERECTOMY; JOINT STIFFNESS; MUSCLE STIFFNESS; SLEEP DISORDER; TUMOR VOLUME; UTERUS MYOMA; VAGINA BLEEDING;

EID: 0030317737     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/11.suppl_3.3     Document Type: Conference Paper

References (143)

1. Adashi, E.Y. (1994) Long-term gonadotrophin-releasing hormone agonist therapy: the evolving issue of steroidal 'add-back' paradigms. Hum. Reprod., 9, 1380-1397.
2. Andreyko, J.L., Blumenfeld, Z., Marshall, L.A. et al. (1988) Use of an agonistic analog of gonadotropin-releasing hormone (nafarelin) to treat leiomyomas: assessment by magnetic resonance imaging. Am. J. Obstet. Gynecol., 158, 903-910.
3. Arimura, A. (1991) The backstage story of the discovery of LHRH. Endocrinology, 129, 1687-1689.
4. Audebert, A.J., Madenelat, P., Querleu, D. et al. (1994) Deferred versus immediate surgery for uterine fibroids: clinical trial results. Br. J. Obstet. Gynaecol., 101 (Suppl. 10), 29-32.
5. Babknia, A., Rock, J.A. and Jones, H.W. (1978) Pregnancy success following abdominal myomectomy for infertility. Fertil. Steril., 30, 644-647.
6. Balasch, J., Gomez, F., Casamitjana, R. et al. (1992) Pituitary-ovarian suppression by the standard and half-doses of D-Trp-6-luteinizing hormone-releasing hormone depot. Hum. Reprod., 7, 1230-1234.
7. Balasch, J., Manau, D., Mimo, J. et al. (1995) Sequential gonadotrophin-releasing hormone agonist/ low-dose oral contraceptive treatment for leiomyomata uteri. Hum. Reprod., 10, 529-532.
8. Barbieri, R.L., Dilena, M., Chumas, J. et al. (1993) Leuprolide acetate depot decreases the number of nucleolar organizer regions in uterine leiomyomata. Fertil. Steril., 60, 569-570.
9. Beck, L.R., Cowsar, D.R., Lewis, D.H. et al. (1979) New long-acting injectable microcapsule contraceptive system. Am. J. Obstet. Gynecol., 135, 419-426.
10. Benagiano, G., Morini, A., Aleandri, V. et al. (1990) Sequential Gn-RH superagonist and medroxyprogesterone acetate treatment of uterine leiomyomata. Int. J. Obstet. Gynecol., 33, 333-343.
11. Bergquist, C. and Lindgren, P. (1983) Ultrasonic measurement of ovarian follicles during chronic LRH agonist treatment for contraception. Contraception, 28, 125-133.
12. Blumenfeld, Z., Thaler, L., Beck, D. and Brandes, J.M. (1990) Treatment of uterin leiomyomata with GnRH analog (nafarelin): a clinical protocol of interrupted (on-off) treatment. Gynecol. Endocrinol., 4, 31.
13. Brandon, D.D., Bethea, C.L., Strawn, E. Y. et al. (1993) Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am. J. Obstet. Gynecol., 169, 78-95.
14. Broekmans, F.J., Bernardus, R.E., Berkhout, G. and Schoemaker, J. (1992) Pituitary and ovarian suppression after early follicular and mid-luteal administration of a LHRH agonist in a depot formulation: decapeptyl CR. Gynecol. Endocrinol., 6, 153-161.
15. Broekmans, F.J., Bernardus, R.E., Broeders, A. et al. (1993) Pituitary responsiveness after administration of a GnRH agonist depot formulation: Decapeptyl CR. Clin. Endocrinol. Oxf., 38, 579-587.
16. Broekmans, F.J., Hompes, P.G., Schoute, E. et al. (1996) 'Draw back' GnRH agonist treatment of uterine leiomyomas: standard followed by reduced dose therapy. Am. J. Obstet. Gynecol., 175, in press.
17. Buttram, V.C. and Reiter, R.C. (1981) Uterine leoimyomata: etiology, symptomatology and management. Fertil. Steril., 36, 433-445.
18. Candiani, G.B., Vercellini, P., Fedele, L. et al. (1990) Use of goserelin depot, a gonadotropin-releasing hormone agonist, for the treatment of menorrhagia and severe anemia in women with leiomyomata uteri. Acta Obstet. Gynecol. Scand., 69, 413-415.
19. Candiani, G.B., Fedele, L., Parazzini, F. and Villa, L. (1991) Risk of recurrence after myomectomy. Br. J. Obstet. Gynaecol., 98, 385-389.
20. Coddington, C.C., Collins, R.L., Shawker, T.H. et al. (1986) Long-acting gonadotropin hormone-releasing hormone analog used to treat uteri. Fertil. Steril., 45, 624-629.
21. Colgan, T.J., Pendergast, S. and LeBlanc, M. (1993) The histopathology of uterine leiomyomas following treatment with gonadotrophin-releasing hormone analogues. Hum. Pathol., 24, 1073-1077.
22. Cramer, S.F. and Patel, D. (1990) The frequency of uterine leiomyomas. Am. J. Clin. Pathol., 94, 435-438.
23. D'Addato, F., Repinto, A. and Andreoli, C. (1992) Pre-surgical treatment of uterine myomas with LH-RH agonists. Clin. Exp. Obstet. Gynecol., 19, 45-50.
24. Dawood, M.Y. (1993) Impact of medical treatment of endometriosis on bone mass. Am. J. Obstet. Gynecol., 168, 674-684.
25. de Ziegler, D., Bessis, R. and Frydman, R. (1991) Vascular resistance of uterine arteries: physiological effects of oestradiol and progesterone. Fertil. Steril., 55, 775-779.
26. Donnez, J., Schrurs, B., Gillerot, S. et al. (1989) Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography. Fertil. Steril., 51, 947-950.
27. Dubuisson, J.B., Lecuru, F., Foulot, H et al. (1991) Myomectomy by laparoscopy: a preliminary report of 43 cases. Fertil. Steril., 56, 827-830.
28. Fahri, J., Ashkenazi, J., Feldberg, D. et al. (1995) Effect of uterine leiomyomata on the results of in vitro fertilization treatment. Hum. Reprod., 10, 2576-2578.
29. Falsetti, L., Mazzani, M.D., Rubessa, S. and Ruggeri, C. (1992) Presurgical treatment of uterine fibroids by using gonadotrophin-releasing hormone agonists. Acta Eur. Fertil., 23, 29-32.
30. Fedele, L., Vercellini, P., Bianchi. S. et al. (1990) Treatment with GnRH agonists before myomectomy and the risk of short-term myoma recurrence. Br. J. Obstet. Gynaecol., 97, 393-396.
31. Fedele, L., Parazzini, F., Luchini, L. et al. (1995) Recurrence of fibroids after myomectomy: a transvaginal ultrasonographic study. Hum. Reprod., 10, 1795-1796.
32. Filicori, M., Hall, D.A., Loughlin, J.S. et al. (1983) A conservative approach to the management uterine leiomyomata: pituitary desensitisation by a luteinizing hormone-releasing hormone analogue. Am. J. Obstet. Gynecol., 147, 726-729.
33. Filicori, M., Flamigni, C., Cognigni, G. et al. (1993) Comparison of the suppressive capacity of different depot gonadotropin-releasing hormone analogs in women. J. Clin. Endocrinol Metab., 77, 130-133.
34. Fogelman, I. (1992) Gonadotropin-releasing hormone agonists and the skeleton. Fertil. Steril., 57, 715-724.
35. Fraser, H.M., Haining, R., Cowen, G.M. et al. (1992) Long-acting gonadotrophin releasing hormone agonist implant causes variable duration of suppression of ovarian steroid and inhibin secretion. Clin. Endocrinol. Oxf., 36, 97-104.
36. Friedman, A.J., Barbieri, R.L., Benacerraf, B.R. and Schiff, I. (1987) Treatment of leiomyomata with intranasal or subcutaneous leuprolide, a gonadotropin-releasing hormone agonist. Fertil. Steril., 48, 560-564.
37. Friedman, A.J., Barbieri, R.L., Doubilet, P.M. et al. (1988) A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertil. Steril., 49, 404-409.
38. Friedman, A.J. (1989a) Vaginal hemorrhage associated with degenerating submucous leiomyomata during leuprolide acetate treatment. Fertil. Steril., 52, 152-154.
39. Friedman, A.J. (1989c) Treatment of leiomyomata uteri with short-term leuprolide followed by leuprolide plus estrogen-progestin hormone replacement therapy for 2 years: a pilot study. Fertil. Steril., 51, 526-528.
40. Friedman, A.J. (1989c) Clinical experience in the treatment of fibroids with leuprolide and other GnRH agonists. Obstet. Gynecol. Surv., 44, 311-313.
41. Friedman, A.J., Garfield, J.M., Rein, M.S. et al. (1989b) A randomized, placebo-controlled, double-blind study evaluating leuprolide acetate depot treatment before myomectomy. Fertil. Steril., 52, 728-733.
42. Friedman, A.J., Harrison Atlas, D., Barbieri, R.L. et al. (1989b) A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata. Fertil. Steril., 51, 251-256.
43. Friedman, A.J., Lobel, S.M., Rein, M.S. and Barbieri, R.L. (1990) Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis. Am. J. Obstet. Gynecol., 163, 1114-1119.
44. Friedman, A.J., Hoffman, D.I., Comite, F. et al. (1991) Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group. Obstet. Gynecol., 77, 720-725.
45. Friedman, A.J., Daly, M., Juneau Norcross, M. et al (1992a) Recurrence of myomas after myomectomy in women pretreated with leuprolide acetate depot or placebo. Fertil. Steril., 58, 205-208.
46. Friedman, A.J., Daly, M., Juneau Norcross, M. and Rein, M.S. (1992b) Predictors of uterine volume reduction in women with myomas treated with a gonadotropin-releasing hormone agonist. Fertil. Steril., 58, 413-415.
47. Friedman, A.J. (1993) Treatment of uterine myomas with GnRH agonists. Sem. Reprod. Endocrinol., 11, 154-161.
48. Friedman, A.J., Daly, M., Juneau Norcross, M. et al (1993) A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin 'add-back' regimens for women with leiomyomata uteri. J. Clin. Endocrinol. Metab., 76, 1439-1445.
49. Friedman, A.J., Daly, M., Juneau-Norcross, M. et al. (1994) Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin 'add back' for 2 years. Hum. Reprod., 9, 1618-1625.
50. Furger, C., Bourrie, N., Cedard, L. et al (1996) Gonadotrophin-releasing hormone and triptorelin inhibit the follicle stimulating hormone-induced response in human primary cultured granulosa-lutein cells. Mol. Hum. Reprod., 2, 259-264.
51. Gallagher, J.C. (1993) Effect of gonadotrophin-releasing hormone agonists on bone metabolism. Sem. Reprod. Endocrinol., 11, 201-208.
52. Garcia, C.R. and Tureck, R.W. (1984) Submucosal leiomyomas and infertility. Fertil Steril., 42, 16-19.
53. Gardner, R.L. and Shaw. R.W. (1992) GnRH agonists and blood loss at surgeryz. In Shaw, R.W. (ed.), Advances in Reproductive Endocrinology. Uterine Fibroids. Time for a Review. Parthenon Publishing Group, Carnforth, pp. 123-134.
54. Geisthoevel, F., Jenne, D., Wieacker, P. and Breckwoldt, M. (1987) Cyclic administration of an LHRH analogue and to progesterone in risk patients to oral contraceptives. Contraception, 36, 459-469.
55. Ginsburg, E.S., Benson, C.B., Garfield, J.M. et al. (1993) The effect of operative technique and uterine size on blood loss during myomectomy: a prospective randomized study. Fertil Steril., 60, 956-962.
56. Golan, A., Bukovsky, I., Schneider, D. et al. (1989) D-Trp-6-luteinizing hormone-releasing hormone microcapsules in the treatment of uterine leiomyomas. Fertil. Steril., 52, 406-411.
57. Golan, A. (1993) Treatment of uterine fibroids with triptorelin in different regimens. Hum. Reprod., 8, 132-135.
58. Golan, A., Bukovsky, I., Pansky, M. et al. (1993) Pre-operative gonadotrophin-releasing hormone agonist treatment in surgery for uterine leiomyomata. Hum. Reprod., 8, 450-452.
59. Goldzieher, J.W., Maqueo, M. and Ricaud, L. (1966) Induction of degenerative change in uterine myomas by high-dose progestin therapy. Am. J. Obstet. Gynecol., 96, 1078-1087.
60. Gonzalez-Barcena, D., Perez-Sanchez, PL., Graef, A. et al. (1989) Inhibition of the pituitary-gonadal axis by a single administration of D-Trp-6-LH-RH (Decapeptyl) in a sustained-release formulation in patients with prostatic carcinoma. Prostate, 14, 291-300.
61. Goodman, A.L. (1946) Progesterone therapy in uterine fibromyoma. J. Clin. Endocrinol. Metab., 6, 402-408.
62. Gudmundsson, J.A., Nillius, S.J. and Bergquist, C. (1984) Inhibition of ovulation by intranasal nafarelin, a new superactive agonist of GnRH. Contraception, 30, 107-112.
63. Gudmundsson, J.A., Nillius, S.J. and Bergquist, C. (1986) Intranasal peptide contraception by inhibition of ovulation with the gonadotropin-releasing hormone superagonist nafarelin: six months' clinical results. Fertil. Steril., 45, 617-623.
64. Gudmundsson, J.A., Lundkvist, O., Bergquist, C. et al. (1987) Endometrial morphology after 6 months of continuous treatment with a new gonadotropin-releasing hormone superagonist for contraception. Fertil. Steril., 48, 52-56.
65. Gutmann, J.N., Thornton, K.L., Diamond, M.P. and Carcangiu, M.L. (1994) Evaluation of leuprolide acetate treatment on histopathology of uterine myomata. Fertil. Steril., 61, 622-626.
66. Hackenberg, R., Gesenhues, T., Deichert, U. et al. (1992) The response of uterine fibroids to GnRH-agonist treatment can be predicted in most cases after one month. Eur. J. Obstet. Gynecol. Reprod. Biol., 45, 125-129.
67. Harrison-Woolrych, M. and Robinson, R. (1996) Fibroid growth in response to high-dose progestogen. Fertil. Steril., 64, 191-192.
68. Healy, D.L., Fraser, H.M. and Lawson, S.L. (1984) Shrinkage of a uterine fibroid after subcutaneous infusion of a LHRH agonist. Br. Med. J. Clin. Res. Ed., 289, 1267-1268.
69. Healy, D.L., Lawson, S.R., Abbott, M. et al. (1986) Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase. J. Clin. Endocrinol. Metab., 63, 619-625.
70. Hitti, I.F., Glasberg, S.S., McKenzie, C. and Meltzer, B.A. (1991) Uterine leiomyosarcoma with massive necrosis diagnosed during gonadotropin-releasing hormone analog therapy for presumed uterine fibroid. Fertil. Steril., 56, 778-780.
71. Huhtaniemi, I.T., Dahl, K.D., Rannikko, S. and Hsueh, A.J. (1988) Serum bioactive and immunoreactive follicle-stimulating hormone in prostatic cancer patients during gonadotropin-releasing hormone agonist treatment and after orchidectomy. J. Clin. Endocrinol. Metab., 66, 308-313.
72. Kawaguchi, K., Fujii, S., Konishi, I. et al. (1989) Mitotic activity in uterine leiomyomas during the menstrual cycle. Am. J. Obstet. Cynecol., 160, 637-641.
73. Kettel, L.M., Murphy, A.A., Morales, A.J. et al. (1993) Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist. Fertil Steril., 60, 642-646.
74. Kettel, L.M., Murphy, A.A., Morales, A.J. and Yen. S.S. (1994) Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Hum. Reprod., 9 (Suppl. 1), 116-120.
75. Kiltz, R.J., Rutgers, J., Phillips, J. et al. (1994) Absence of a dose-response effect of leuprolide acetate on leiomyomata uteri size. Fertil. Steril., 61, 1021-1026.
76. Lamminen, S., Rantala, I., Helin, H. et al. (1992) Proliferative activity of human uterine leiomyoma cells as measured by automatic image analysis. Gynecol. Obstet. Invest, 34, 111-114.
77. Leather, A.T., Studd, J.W., Watson, N.R. and Holland, E.F. (1993) The prevention of bone loss in young women treated with GnRH analogues with 'add-back' estrogen therapy. Obstet. Gvnecol., 81, 104-107.
78. Leiberman, J.R., Wiznitzer, A., Glezerman, M. et al. (1993) Estrogen and progesterone receptors in the uterine artery of rats during and after pregnancy. Eur. J. Obstet. Gynecol. Reprod. Biol., 51, 35-40.
79. Lemay, A., Faure, N., Labrie, F. and Fazekas, A.T. (1985) Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding. Fertil. Steril., 43, 868-877.
80. Letterie, G.S., Coddington, C.C., Winkel, C.A. et al. (1989) Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: long-term follow-up. Fertil. Steril., 51, 951-956.
81. Letterie, G.S., Stevenson, D. and Shah, A. (1991) Recurrent anaphylaxis to a depot form of GnRH analogue. Obstet. Gynecol., 78, 943-946.
82. Lumsden, M.A., West, C.P., Bramley, T. et al. (1988) The binding of epidermal growth factor to the human uterus and leiomyomata in women rendered hypo-oestrogenic by continuous administration of an LHRH agonist. Br. J. Obstet. Gynaecol., 95, 1299-1304.
83. Lumsden, M.A., West, C.P., Hawkins, R.A. et al. (1989a) The binding of steroids to myometrium and leiomyomata (fibroids) in women treated with the gonadotrophin-releasing hormone agonist Zoladex (ICI 118630). J. Endocrinol., 121, 389-396.
84. Lumsden, M.A., West, C.P., Hillier, H. and Baird, D.T. (1989b) Estrogenic action of tamoxifen in women treated with luteinizing hormone-releasing hormone agonists (goserelin)-lack of shrinkage of uterine fibroids. Fertil. Steril., 52, 924-929.
85. Lumsden, M.A., West, C.P., Thomas, E. et al. (1994) Treatment with the gonadotrophin releasing hormone-agonist goserelin before hysterectomy for uterine fibroids. Br. J. Obstet. Gynaecol., 101, 438-442.
86. Lundkvist, O. and Bergquist, C. (1986) Morphological studies of human endometrium during continuous LH-RH agonist treatment. Int. J. Fertil., 30, 65-70.
87. Maheux, R., Guilloteau, C., Lemay, A. et al. (1984) Regression of leiomyomata uteri following hypooestrogenism induced by repetitive luteinizing hormone-releasing hormone agonist treatment: preliminary report. Fertil Steril., 42, 644-646.
88. Maheux, R., Lemay, A. and Merat, P. (1987) Use of intranasal luteinizing hormone-releasing hormone agonist in uterine leiomyomas. Fertil. Steril., 47, 229-233.
89. Maheux, R., Lemay, A. and Turcot Lemay, L. (1988) Dose-related inhibition of acute luteinizing hormone response during luteinizing hormone-releasing hormone agonist treatment for uterine leiomyoma. Am. J. Obstet. Gynecol., 158, 361-364.
90. Maheux, R., Lemay, A., Blanchet, P. et al. (1991) Maintained reduction of uterine leiomyoma following addition of hormonal replacement therapy to a monthly luteinizing hormone-releasing hormone agonist implant: a pilot study. Hum. Reprod., 6, 500-505.
91. Maheux, R. and Lemay, A. (1992) Treatment of peri-menopausal women: potential long-term therapy with a depot GnRH agonist combined with hormonal replacement therapy. Br. J. Obstet. Gynaecol., 99 (Suppl. 7), 13-17.
92. Matta, W.H., Shaw, R.W. and Burford, G.D. (1988a) Endocrinologic and clinical evaluation following a single administration of a gonadotropin-releasing hormone agonist (Zoladex), in a depot formulation, to premenopausal women. Fertil. Steril., 49, 163-165.
93. Matta, W.H., Stabile, I., Shaw, R.W. and Campbell, S. (1988b) Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin-releasing hormone agonist Buserelin. Fertil. Steril., 49, 1083-1085.
94. Matta, W.H., Shaw, R.W. and Nye, M. (1989) Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin. Br. J. Obstet. Gynaecol., 96, 200-206.
95. Mezrow, G., Shoupe, D., Spicer, D. et al. (1994) Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome. Fertil. Steril., 62, 932-937.
96. Monroe, S.E., Blumenfeld, Z., Andreyko, J.L. et al. (1986) Dose-dependent inhibition of pituitary-ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (nafarelin) J. Clin. Endocrinol Metab., 63, 1334-1341.
97. Murphy, A.A., Kettel, L.M., Morales, A.J. et al. (1993) Regression of uterine Ieiomyomata in response to the antiprogesterone RU 486. J. Clin. Endocrinol. Metab., 76, 513-517.
98. Murphy, N.J. and Wallace, D.L. (1993) Gonadotropin releasing hormone (GnRH) agonist therapy for reduction of leiomyoma volume. Gynecol. Oncol., 49, 266-267.
99. Nakamura, Y., Yoshimura, Y., Yamada, H. et al. (1991) Treatment of uterine leiomyomata with a luteinizing hormone-releasing hormone agonist: the possibility of nonsurgical management in selected perimenopausal women. Fertil. Steril., 55, 900-905.
100. Neuman, M., Langer, R., Golan, A. et al. (1991) Gonadotropin-releasing hormone (GnRH) action on uterine leiomyomata is not mediated by uterine GnRH receptors. Fertil. Steril., 56, 364-366.
101. Nillius, S.J. (1985) Gonadotropin releasing hormone analogs for female contraception by inhibition of ovulation. J. Steroid Biochem., 23, 849-854.
102. Paoletti, A.M., Guerriero, S., Serra, G.G. et al. (1996) Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment. Fertil Steril., 65, 707-710.
103. Perl, V., Marquez, J., Schally, A.V. et al. (1987) Treatment of Ieiomyomata uteri with D-Trp6-luteinizing hormone-releasing hormone. Fertil. Steril., 48, 383-389.
104. Prince, R.L. (1994) Counterpoint: estrogen effects on calcitropic hormones and calcium hemostasis. Endocr. Rev., 15, 301-309.
105. Rein, M.S., Friedman, A.J., Stuart, J.M. and MacLaughlin, D.T. (1990) Fibroid and myometrial steroid receptors in women treated with gonadotropin-releasing hormone agonist leuprolide acetate. Fertil. Steril., 53, 1018-1023.
106. Rein, M.S., Barbieri, R.L., Welch, W. et al. (1993) The concentrations of collagen-associated amino acids are higher in GnRH agonist-treated uterine myomas. Obstet. Gynecol., 82, 901-905.
107. Rein, M.S., Barbieri, R.L. and Friedman, A.J. (1995) Progesterone: a critical role in the pathogenesis of uterine myomas. Am. J. Obstet. Gynecol., 172, 14-18.
108. Resnik, R., Killam, A.P., Battaglia, F.C. et al. (1974) The stimulation of uterine blood flow by various estrogens. Endocrinology, 94, 1192-1196.
109. Rosenfeld, D.L. (1986) Abdominal myomectomy for otherwise unexplained infertility. Fertil. Steril., 46, 328-330.
110. Ross, R.K., Pike, M.C., Vessey, M.P. et al. (1986) Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br. Med. J., 293, 359-363.
111. Scheele, F., Hompes, P.G., Lambalk, C.B. et al. (1996) The gonadotrophin-releasing hormone (GNRH) challenge test: a quantitative measure of pituitary desensitization during GNRH-agonist administration. Clin. Endocrinol. Oxf., 44, 581-586.
112. Schlaff, W.D., Zerhouni, E.A., Huth, J.A. et al. (1989) A placebo-controlled trial of a depot gonadotropin-releasing hormone analogue (leuprolide) in the treatment of uterine leiomyomata. Obstet. Gynecol., 74, 856-862.
113. Schwartz, L.B., Diamond, M.P. and Schwartz, P.E. (1993) Leiomyosarcomas: clinical presentation. Am. J. Obstet. Gynecol.
114. Scialli, A.R., Jestila, K.J. and Simon, J.A. (1993) Leuprolide acetate and bone mineral density measured by quantitative digitized radiography. Fertil. Steril., 59, 674-676.
115. Scialli, A.R. and Jestila, K.J. (1996) Sustained benefits of leuprolide acetate with or without subsequent medroxyprogesterone acetate in the nonsurgical management of leiomyoma uteri. Fertil. Steril., 64, 313-320.
116. Segaloff, A., Wead, J.C., Sternberg, W.H. and Parson, W. (1959) The progesterone therapy of human uterine leiomyomas. J. Clin. Endocrinol. Metab., 9, 1273-1291.
117. Shek, Y.H., Stastny, J.J. and Fosslien, E. (1987) Effect of menstrual cycle on protein expression in human uterine leiomyomas. Obstet. Gynecol., 70, 128-133.
118. Sherman, B., Chapler, F., Crickard, K. and Wycoff, D. (1979) Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women. J. Clin. Invest., 64, 398-404.
119. Smitz, J., Van Dessel, A., Camus, M. et al. (1990) Comparison of different dosage regimens of LHRH analogues in GIFT, ZIFT or IVF. In Brosens, I., Jacobs, H.S. and Runnebaum, B. (eds), LHRH Analogues in Gynaecology. Parthenon Publishing, Carnforth, UK, pp. 35-42.
120. Stewart, E.A. and Friedman, A.J. (1992) Steroidal treatment of myomas: preoperative and long-term medical therapy. Sem. Reprod. Endocrinol., 10, 344-357.
121. Stovall, T.G., Ling, F.W., Henry, L.C. and Woodruff, M.R. (1991) A randomized trial evaluating leuprolide acetate before hysterectomy as treatment for leiomyomas. Am. J. Obstet. Gynecol., 164, 1420-1423.
122. Sugimoto, A.K., Hodsman, A.B. and Nisker, J.A. (1993) Long-term gonadotropin-releasing hormone agonist with standard postmenopausal estrogen replacement failed to prevent vertebral bone loss in premenopausal women. Fertil Steril., 60, 672-674.
123. Surrey, E.S. and Judd, H.L. (1992) Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. J. Clin. Endocrinol. Metab., 75, 558-563.
124. Tulandi, T., Murray, C. and Guralnick, M. (1993) Adhesion formation and reproductive outcome after myomectomy and second-look laparoscopy. Obstet. Gynecol., 82, 213-215.
125. Turner, R.T., Riggs, B.L. and Spelsberg, TC. (1994) Skeletal effects of estrogen. Endocr. Rev., 15, 275-300.
126. Uemura, T., Minaguchi, H., Mizuno, M. et al. (1990) The effects of GnRH agonist (buserelin) on uterine leiomyoma: clinical study on finding the optimal dose. In Brosens, I., Jacobs, H.S. and Runnebaum. B, (eds), LHRH Analogues in Gynaecology. Parthenon Publishing, Carnforth, UK, pp. 101-110.
127. Uemura, T., Minaguchi, H., Okuda, K. and Sugimoto, O. (1992) GnRH agonist Zoladex in the treatment of endometriosis. In Lunenfeld, B. (ed.), Advances in the study of GnRH analogues. Proceedings of the 2nd international symposium on GnRH analogues in cancer and human reproduction. Parthenon Publishing. Carnforth, UK, pp. 159-171.
128. Uemura, T., Suzuki, N., Mohri, J. et al. (1994) Effect of gonadotropin-releasing hormone agonist on the bone mineral density of patients with endometriosis. Fertil. Steril., 62, 246-250.
129. Upadhyaya, N.B., Doody, M.C. and Googe, P.B. (1990) Histopathological changes in leiomyomata treated with leuprolide acetate. Fertil. Steril., 54, 811-814.
130. van Leusden, H.A. (1992) Symptom-free interval after triptorelin treatment of uterine fibroids: long-term results. Gynecol. Endocrinol., 6, 189-198.
131. van Leusden, H.A. and Dogterom, A.A. (1988) Rapid reduction of uterine leiomyomas with monthly injections of D-Trp6-GnRH. Gynecol. Endocrinol., 2, 45-51.
132. Vercellini, P., Bocciolone, L., Colombo, A. et al. (1993) Gonadotropin releasing hormone agonist treatment before hysterectomy for menorrhagia and uterine leiomyomas. Acta Obstet. Gynecol. Scand., 72, 369-373.
133. Verkauf, B.S. (1992) Myomectomy for fertility enhancement and preservation. Fertil. Steril., 58, 1-15.
134. Vollenhoven, B.J., Shekleton, P., McDonald, J. and Healy, D.L. (1990) Clinical predictors for buserelin acetate treatment of uterine fibroids: a prospective study of 40 women. Fertil. Steril., 54, 1032-1038.
135. Waibel Treber, S., Minne, H.W., Scharla, S.H. et al. (1989) Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma. Hum. Reprod., 4, 384-388.
136. Watanabe, Y. and Nakamura, G. (1995) Effects of two different doses of leuprolide acetate depot on uterine cavity area in patients with uterine leiomyomas. Fertil. Steril., 63, 487-490.
137. Watanebe, Y., Nozaki, M., Nakamura, G. et al. (1992) Efficacy of low-dose leuprolide acetate depot in the treatment of uterine leiomyomata in Japanese women. Fertil. Steril., 58, 66-71.
138. West, C.P., Lumsden, M.A., Lawson, S. et al. (1987) Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot. Fertil. Steril., 48, 45-51.
139. West, C.P., Lumsden, M.A., Hillier, H. et al. (1992) Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical management of uterine fibroids. Hum. Reprod., 7, 328-332.
140. Whitehouse, R.W., Adams, J.E., Bancroft, K. et al. (1990) The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis. Clin. Endocrinol. Oxf., 33, 365-373,
141. Wiznitzer, A., Marbach, M., Hazum, E. et al. (1988) Gonadotropin-releasing hormone specific binding sites in uterine leiomyomata. Biochem. Biophys. Res. Commun., 152, 1326-1330.
142. Ylikorkala, O., Tiitinen, A., Hulkko, S. et al. (1995) Decrease in symptoms, blood loss and uterine size with nafarelin acetate before abdominal hysterectomy: a placebo-controlled, double-blind study. Hum. Reprod., 10, 1470-1474.
143. Zorn, J.R., Barata, M., Brami, C. et al. (1988) Ovarian stimulation for in viiro fertilization and GIFT combining administration of gonadotrophins and blockade of the pituitary with D-Trp6-LH-RH. Eur. J. Obstet. Gynecol. Reprod. Biol., 28, 116-120.